Drug intelligence / Profile preview

HCP1903

Development stage: Phase 1
Lead developer: Hanmi Pharmaceutical
Administration: Oral

Overview

HCP1903 is an orally administered drug developed by Hanmi Pharmaceutical Company Limited. It is currently undergoing clinical investigation for the treatment of primary hypercholesterolemia. Studies have evaluated its efficacy, safety, pharmacokinetics, and tolerability.

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)NPC1L1 (Niemann-pick C1-Like 1 transporter)

Beyond the preview

Go deeper on HCP1903.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HCP1903.

Explore the full profile